Felzartamab
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Immunoglobulin A (IgA) Nephropathy
Conditions
Immunoglobulin A (IgA) Nephropathy
Trial Timeline
Aug 31, 2021 → May 6, 2024
NCT ID
NCT05065970About Felzartamab
Felzartamab is a phase 2 stage product being developed by Biogen for Immunoglobulin A (IgA) Nephropathy. The current trial status is completed. This product is registered under clinical trial identifier NCT05065970. Target conditions include Immunoglobulin A (IgA) Nephropathy.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07444489 | Phase 3 | Recruiting |
| NCT06064929 | Phase 1 | Active |
| NCT05065970 | Phase 2 | Completed |
Competing Products
11 competing products in Immunoglobulin A (IgA) Nephropathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ABBV-383 (Etentamig) | AbbVie | Phase 1/2 | 41 |
| zigakibart | Novartis | Phase 2 | 52 |
| iptacopan | Novartis | Phase 3 | 77 |
| CCX168 | Amgen | Phase 2 | 51 |
| Inebilizumab | Amgen | Phase 2 | 51 |
| Rilzabrutinib + Placebo + Glucocorticoid | Sanofi | Phase 3 | 76 |
| rilzabrutinib + Glucocorticoids | Sanofi | Phase 2 | 51 |
| Felzartamab + Placebo | Biogen | Phase 3 | 74 |
| Sparsentan | Travere Therapeutics | Phase 2 | 47 |
| Sparsentan | Travere Therapeutics | Phase 2 | 47 |
| sparsentan + irbesartan + Dapagliflozin | Travere Therapeutics | Phase 3 | 72 |